KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $149.5 million.

  • Emergent BioSolutions' Receivables - Net rose 2324.81% to $149.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.5 million, marking a year-over-year increase of 2324.81%. This contributed to the annual value of $154.5 million for FY2024, which is 1910.99% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Receivables - Net stood at $149.5 million, which was up 2324.81% from $79.8 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Receivables - Net ranged from a high of $290.1 million in Q2 2023 and a low of $79.8 million during Q2 2025
  • Over the past 5 years, Emergent BioSolutions' median Receivables - Net value was $189.2 million (recorded in 2022), while the average stood at $193.5 million.
  • Per our database at Business Quant, Emergent BioSolutions' Receivables - Net skyrocketed by 6577.14% in 2023 and then plummeted by 5934.79% in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Receivables - Net stood at $278.9 million in 2021, then crashed by 42.92% to $159.2 million in 2022, then rose by 19.97% to $191.0 million in 2023, then decreased by 19.11% to $154.5 million in 2024, then dropped by 3.24% to $149.5 million in 2025.
  • Its last three reported values are $149.5 million in Q3 2025, $79.8 million for Q2 2025, and $203.7 million during Q1 2025.